Daré Bioscience, Inc. (DARE)
| Market Cap | 53.48M |
| Revenue (ttm) | 2.82M |
| Net Income (ttm) | -28.87M |
| Shares Out | 101.09M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 662,552 |
| Open | 0.510 |
| Previous Close | 0.485 |
| Day's Range | 0.480 - 0.520 |
| 52-Week Range | 0.270 - 1.020 |
| Beta | 1.31 |
| Analysts | Strong Buy |
| Price Target | 4.50 (+769.23%) |
| Earnings Date | May 14, 2024 |
About DARE
Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female g... [Read more]
Financial Performance
In 2023, DARE's revenue was $2.81 million, a decrease of -71.92% compared to the previous year's $10.00 million. Losses were -$30.16 million, -2.54% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for DARE stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 769.23% from the latest price.
News
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the Un...
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
Daré joins a nationwide network working to accelerate transformative health solutions Daré joins a nationwide network working to accelerate transformative health solutions
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts
$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to Dar...
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience's DARE-LARC1 Platform Technology has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has the ...
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription in the United States to treat bacterial vaginosis under license agreement w...
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 ...
This overlooked corner of women's health could be a $350 billion market opportunity
Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
There are no FDA-approved treatments for female sexual arousal disorder There are no FDA-approved treatments for female sexual arousal disorder
Daré Bioscience Announces Executive Team and Board of Directors Changes
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement o...
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
Grant funds support activities that will aid the ultimate development of bacteria-based biotherapeutic products designed to benefit women and newborns Grant funds support activities that will aid the ...
Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases
Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged Trea...
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
$5 million at closing and up to $7 million of additional committed funding $5 million at closing and up to $7 million of additional committed funding
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary Dysmenorrhea Data Support Continued Clinical Development of DARE-PDM1 and its Po...
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study
DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options
Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of $1.8 million triggered by achievement of first commercial milestone under license agreem...
Daré Bioscience to Participate in Three November Conferences
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that the company's President and CEO, Sabrina Martucci Johnson...
Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program
Additional Analyses of Phase 2b Data Conducted in Population of Study Participants with Female Sexual Interest/Arousal Disorder (FSIAD), With Primary Complaint of Arousal Dysfunction
Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it has entered into a definitive agreement with an instit...
Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)): XACIATO™ First Commercial Sale Ovaprene® (hormone-free monthly contraception) – Pivota...
Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings
SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced the publication of positive preliminary efficacy results from ...
Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p...
Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems
SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that the company's Chief Scientific Officer, David Friend, Ph....
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause
Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and CEO...